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Background: Human challenge models using respiratory viruses such as influenza are increasingly utilised in the
development of novel vaccines and anti-viral modalities and can provide preliminary evidence of protection before
evaluation in field trials. We describe the results of a clinical study characterising an A/H1N1 influenza challenge
virus in humans.
Methods: The challenge agent, influenza A/California/2009 (H1N1), was manufactured under cGMP conditions and
characterised in accordance with regulatory guidelines. A dose-ascending open-label clinical study was conducted
in 29 healthy young adults screened sero-negative to the challenge strain. Subjects were intranasally inoculated
with three increasing doses of virus and physician-reported signs, subjected-reported symptoms, viral shedding and
immunological responses were monitored.
Results: A dose-dependent increase in clinical signs and symptoms was observed with 75% of subjects developing
laboratory-confirmed illness at the highest inoculum (3.5 × 106 TCID50). At the highest dose, physician or subject-
reported signs of infection were classified as mild (all subjects), moderate (50%) and severe (16%) with peak
symptoms recorded four days after infection. Clinical signs were correlated with nasal mucus weight (P < .001) and
subject-reported symptoms (P < .001). Geometric mean peak viral shedding was log10 5.16 TCID50 and occurred
three days after inoculation with a median duration of five days. The safety profile was such that physiological
responses to viral infection were mainly restricted to the upper airways but were not of such severity to be of
clinical concern.
Conclusions: A highly characterised wild-type Influenza A/California/2009 (H1N1) virus manufactured for clinical
use was shown to induce a good infectivity profile in human volunteers. This clinical challenge model can be used
for evaluating potential efficacy of vaccines and anti-viral therapeutics.
Trial registration: NCT02014870
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Influenza A is a major global health concern with
seasonal influenza epidemics affecting 5 to 15% of the
population, resulting in severe illness in 3 to 5 million
patients and approximately 250,000 to 500,000 deaths
per year [1]. Hospitalisation and deaths mainly occur* Correspondence: james.francis@its-innovation.com
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unless otherwise stated.in high-risk groups, in particular children younger than
age two, adults age 65 or older, and people of any age with
certain medical conditions, such as chronic heart, lung,
kidney, liver, blood or metabolic diseases (such as dia-
betes), or weakened immune systems [2].
Effective control of influenza requires the use of vac-
cines and antiviral treatments. Whilst traditional influenza
vaccines can offer a high level of protection in healthy
adults, reduced efficacy is observed in high-risk groups
[1]. New strategies are being investigated to develop morel. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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fluenza including universal influenza vaccines [3-5]. Emer-
gence of antiviral resistance amongst circulating influenza
strains exemplifies the required development of novel
prophylactic and therapeutic strategies [6].
Experimentally infecting healthy volunteers with a well
characterised influenza virus provides a unique oppor-
tunity to evaluate new intervention strategies under con-
trolled conditions in proof of concept studies. Such trials
can establish pharmacological activity in humans and help
identify correlates of protection. Data from challenge stud-
ies can also contribute to dose selection and understand-
ing of timing of intervention before progressing to larger
field-based studies.
Here we describe the characterisation and clinical
validation of an influenza A/H1N1 challenge virus, iso-
lated during the 2009 ‘swine-flu’ pandemic, suitable for
use in human challenge studies.
Results
Clinical study
A total of 29 healthy human volunteers aged between 22
and 45 (median 38) were infected with a live influenza A
virus, A/California/2009, in an open-label, dose-escalation
clinical study (Table 1). All enrolled volunteers were sero-
negative to the challenge strain and were isolated in a
quarantine unit from 24 hours prior to challenge to 7 days
after challenge. Signs and symptoms of influenza were
recorded via a targeted physical examination assessed by a
physician and subject scoring card respectively. Body
temperature was measured every 4 h during the day to as-
sess for presence of fever. Nasal washes were performed
daily to determine viral shedding. We initially challenged
5 volunteers with a 1:1000 dilution (Cohort 1) of the virus
(~3.5 × 104 TCID50), followed by 12 subjects (Cohort 2) at
1:100 dilution (~3.5 × 105 TCID50) and a further 12 sub-
jects (Cohort 3) at a 1:10 dilution (~3.5 × 106 TCID50). Be-
fore progressing to Cohorts 2 and 3, safety and infectivity
data was reviewed by a safety review committee.Table 1 Subject characterisation
Parameter Cohort 1 Cohort 2
1/1000 dilution of neat virus 1/100 dil
N = 5 N = 12
Age, years; Median (range) 40.0 (39; 45) 35.0 (22; 4
Height, cm; Median (range) 165.5 (154; 180) 168.3 (15
Weight, kg; Median (range) 62.4 (56; 78) 68.0 (50; 9
Sex, n (% Female); Female 2 (40.0) 9 (75.0)
Race, n (%)
Asian 1 (20.0) 0
White 4 (80.0) 12 (100.0
N = number of subjects per cohort; n = number of subjects with that observation.Safety and tolerability
Viral challenge was expected to induce symptoms/signs
typical of influenza infection and were captured as in-
fectivity endpoints in the study and not as adverse
events, unless they were graded as severe by either the
subject or investigator. Across the study, no serious ad-
verse events (SAEs) were recorded. Additional file 1:
Table S1 summarises all treatment-emergent adverse
events (TEAE) that were reported during the quarantine
phase. 3 (60.0%) subjects of Cohort 1, 6 (50.0%) subjects
of Cohort 2, and 5 (41.7%) subjects of Cohort 3 had re-
ported at least one TEAE. In total, 14 subjects (48.3%)
reported 34 events. Most TEAEs were mild or moderate
in severity. There were no clinically significant or per-
sistent shifts in safety laboratory values reported. One
subject in Cohort 2 (202) had an elevated absolute neu-
trophil count (10.04 × 109/L) and total white cell count
(13.9 × 109/L) two days after challenge. Three subjects
in Cohort 2 (206, 209, and 211) and 2 subjects in Cohort
3 (301 and 304) experienced elevated C-reactive proteins
in the range of 16.3 to 56.1 mg/L generally peaking 4 or
5 days post challenge. Monocytes were elevated above
the upper limit of normal on at least one time occasion
post challenge in 60%, 58.3% and 75% subjects in Co-
horts 1, 2 and 3 respectively. The highest values oc-
curred in Cohort 3. Interestingly, there was a statistically
significant negative correlation between lymphocyte to
monocyte ratio (L:M) and clinical symptoms (P = 0.008,
r = -0.725) in cohort 3. There were no other clinically
significant changes in ECG results (ischaemia, pericardi-
tis and tachycardia), respiratory function or vital signs.
Influenza-like illness
There was a dose-dependent increase in subjects with at
least one physician-reported sign of influenza - 20, 75
and 100% in cohorts 1 (1:1000), 2 (1:100) and 3 (1:10)
respectively (Figure 1). With regard to subject-reported
symptoms, there did not appear to be an overall differ-
ence between cohorts 2 and 3 in either the proportionCohort 3 All subjects
ution of neat virus 1/10 dilution of neat virus
N = 12 N = 29
4) 39.5 (25; 45) 38.0 (22; 45)
3; 180) 175.0 (155; 184) 173.3 (153; 184)
0) 74.2 (50; 97) 68.7 (50; 97)
4 (33.3) 16 (55.2)
0 1 (3.4)
) 12 (100.0) 28 (96.6)
Figure 1 Summary of clinical, virological and immunological responses. Data from individual subjects is ranked per cohort according to
physician-reported signs. Physician-reported signs: Data is shown as the cumulative number of clinical signs reported after influenza challenge
during the quarantine period. For each subject, mild, moderate and severe clinical signs are shown as a stacked bar graph with no weighting of
data applied. Fever of greater than 37.7°C is shown as a symbol next to the bar where appropriate. Subject-reported symptoms: As for clinical
signs but reporting the sum of the subject-reported symptoms. Nasal discharge weight: Data is shown as the cumulative nasal discharge weight
in grams. Lymp:Monocyte ratio: The lymphocyte to monocyte ratio was calculated from haematology results collected 5 days after infection. Viral
shedding (rRT-PCR): The results are shown as the cumulative virus copies/mL during the quarantine period. Serology: Geometric mean HI titres to
A/California/7/2009 are shown from serum samples collected at 28 days after challenge. HI tires at screening and one day prior to challenge were
all negative (≤10).
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Table 2 summarises the specific subject-reported symp-
toms and physician-reported signs. Across all cohorts,
the most common symptoms were headache (44.8%),
nasal stuffiness/congestion (41.4%), sore throat (37.9%)
and sneezing (37.9%). The most common physician-
reported signs were pharyngitis (62.1%) and nasal dis-
charge (55.2%). There was a dose-dependent increase in
pharyngitis with 20, 58.3 and 83.3% of subjects showing
signs of pharyngitis in cohorts 1, 2 and 3 respectively.
Most signs and symptoms indicate an upper respiratory
tract infection although some symptoms and signs of a
lower respiratory tract infection were recorded including
new wheezes/crackles/rhonchi (6.9%) and wheezy chest
(3.4%). The severity of individual signs and symptoms
from the highest dose cohort (cohort 3) is shown in
Table 3. All subjects in this group had signs or symptomsclassified as mild, 58.3% had symptoms or signs for at least
one day that were was classified as moderate and 16.7% of
subjects had signs or symptoms defined as severe.
Seven incidences of fever defined as a temperature
of >37.7°C were reported with no association to a
specific dose group (Table 4). One subject in cohort 3
(subject 304) experienced a fever classified as severe
and showed a maximum temperature of 39.4°C in the
evening of Day 2, which was not sustained for any
duration to cause clinical concern, but did peak again
on Day 4 (39.4°C), before returning to normal by the
morning of Day 5.
A significant correlation was measured between nasal
discharge weight and subject symptom scores (r = 0.804,
P = 0.003) or physician-reported sign scores (r = 0.844,
P = 0.001) in the 1:10 dose group (cohort 3). The kinetics
of subject symptoms scores and nasal discharge from
Table 2 The maximum recorded symptom or sign present
during the quarantine phase in cohort 3 (N = 12)
Mild Moderate Severe All
Subject-reported symptoms n % n % n % n %
Headache 4 33.3 2 16.7 1 8.3 7 58.3
Nasal stuffiness/congestion 3 25.0 2 16.7 0 0 5 41.7
Sore throat 3 25.0 2 16.7 0 0 5 41.7
Sneezing 3 25.0 3 25.0 0 0 6 50.0
Cough 2 16.7 2 16.7 1 8.3 5 41.7
Hot/feverish/chills/rigor 3 25.0 1 8.3 0 0 4 33.3
Runny nose 4 33.3 0 0 1 8.3 5 41.7
Musculoskeletal ache 1 8.3 0 0 2 16.6 3 25.0
Fatigue 2 16.7 1 8.3 0 0 3 25.0
Breathing difficulty 3 16.7 0 0 0 0 3 25.0
Diarrhoea 1 8.3 1 8.3 0 0 2 16.7
Earache 2 16.7 0 0 0 0 2 16.7
Facial or eye pain 2 16.7 0 0 1 8.3 3 25.0
Hoarseness 1 8.3 0 0 0 0 1 8.3
Nausea/vomiting 1 8.3 0 0 0 0 1 8.3
Wheezy chest 1 8.3 0 0 0 0 1 8.3
Physician-reported signs n % n % n % n %
Pharyngitis 10 83.3 0 0 0 0 10 83.3
Nasal discharge 3 25.0 3 25.0 2 16.6 8 66.7
Otitis 2 16.6 4 33.3 0 0 6 50.0
Sinus tenderness 2 16.6 0 0 0 0 2 16.7
New wheezes/crackles/rhonchi 1 8.3 1 8.3 0 0 2 16.7
Percussion 0 0 0 0 0 0 0 0
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virus challenge (Figure 2).
Viral shedding
Presence of virus in nasal washes, as determined by rRT-
PCR, was demonstrated in 2 (40%) subjects in cohort 1
(1:1000); 5 (41.6%) subjects in cohort 2 (1:100) and 9
(75%) subjects in cohort 3 (1:10) (Figure 1). Analysis of
the kinetics of viral shedding reveals that there was a











1:1000 5 20 40 40
1:100 12 41.6 50 75
1:10 12 75 50 100
aNeat virus was 3.5 × 107 TCID50.
bAssessed using a rRT-PCR assay.
cSeroconversion defined as a fold increase in serum HI titres of ≥4.
dMild clinical illness defined as one mild physician-reported sign or subject-reported
eModerate clinical illness defined as one moderate physician-reported sign or subje
fLab-confirmed illness defined as mild or moderate clinical illness + positive rRT-PCRduration of viral shedding (Figure 2). Of the two subjects
in cohort 1 with measureable viral shedding, the median
duration of shedding was 1.5 days. For cohorts 2 and 3,
the median duration of viral shedding was 3 and 5.5 days
respectively. The mean maximal magnitude of viral
shedding for cohorts 1, 2 and 3 was 0.99, 1.44 and 2.40
log10 viral copies/mL of nasal wash respectively.
As the 1:10 was identified as the optimal dose of virus
to induce both clinical illness and viral shedding, we fur-
ther conducted measurements of viral infectivity using a
TCID50 assay from this cohort only (Figure 3). Virus was
detected in nasal wash samples 1 day after inoculation in
75% of subjects. Peak viral replication occurred 3 or
4 days after challenge and the geometric mean peak
TCID50 was 10
5.16. The median duration of viral shedding
was 5 days. 25% of subjects in the 1:10 group showed evi-
dence of residual viral shedding 7 days after challenge, the
day of discharge from the quarantine unit.
Serological responses
Volunteers were pre-screened so that all subjects had a
baseline HI titre of ≤1:10 to the challenge virus. HI titres
were additionally measured 28 days after challenge and a
4-fold increase in HI titre was observed in 48% of sub-
jects with no clear association between virus dose and a
positive serological response (Figure 1).
Assessing subject signs and symptoms together with
laboratory assessments (rRT-PCR and/or seroconver-
sion) we defined 20% (1:1000 group), 66% (1:100 group)
and 75% (1:10 group) of subjects will mild laboratory-
confirmed illness (Table 3). 20, 41.6 and 50% of subjects
from cohorts 1, 2 and 3 respectively, had moderate
laboratory-confirmed illness.
Discussion
We have characterised a live, wild-type influenza A virus
isolated from a human sample during the 2009 H1N1
pandemic. A low-passage GMP batch of virus was
manufactured and subjected to extensive quality and ad-
ventitious agent testing, showing close identity to A/
California/04/09 (H1N1) based on sequence and sero-













result or seroconversion or both.
Table 4 Frequencies of subject-reported symptoms, physician-reported signs and pyrexia from cohorts 1 to 3
Cohort 1 (N = 5) Cohort 2 (N = 12) Cohort 3 (N = 12) All (N = 29)
Subject-reported symptoms n % n % n % n %
Headache 2 40.0 4 33.3 7 58.3 13 44.8
Nasal stuffiness/congestion 2 40.0 5 41.7 5 41.7 12 41.4
Sore throat 1 20.0 5 41.7 5 41.7 11 37.9
Sneezing 1 20.0 4 33.3 6 50.0 11 37.9
Cough 1 20.0 4 33.3 5 41.7 10 34.5
Hot/feverish/chills/rigor 1 20.0 5 41.7 4 33.3 10 34.5
Runny nose 1 20.0 3 25.0 5 41.7 9 31.0
Musculoskeletal ache 2 40.0 3 25.0 3 25.0 8 27.6
Fatigue 2 40.0 3 25.0 3 25.0 8 27.6
Breathing difficulty 1 20.0 2 16.7 3 25.0 6 20.7
Diarrhoea 0 0.0 4 33.3 2 16.7 6 20.7
Earache 0 0.0 3 25.0 2 16.7 5 17.2
Facial or eye pain 0 0.0 2 16.7 3 25.0 5 17.2
Hoarseness 1 20.0 1 8.3 1 8.3 3 10.3
Nausea/vomiting 0 0.0 2 16.7 1 8.3 3 10.3
Wheezy chest 0 0.0 0 0.0 1 8.3 1 3.4
Physician-reported signs n % n % n % n %
Pharyngitis 1 20.0 7 58.3 10 83.3 18 62.1
Nasal discharge 0 0.0 8 66.7 8 66.7 16 55.2
Otitis 0 0.0 0 0.0 6 50.0 6 20.7
Sinus tenderness 0 0.0 3 25.0 2 16.7 5 17.2
New wheezes/crackles/rhonchi 0 0.0 0 0.0 2 16.7 2 6.9
Percussion 0 0.0 0 0.0 0 0.0 0 0.0
Pyrexia n % n % n % n %


























Cohort 3; 1:10 (n=9/12)
Cohort 2; 1:100 (n=5/12)
Cohort 1; 1:1000 (n=2/5)
Figure 2 Kinetics of Virus Shedding in infected subjects. Viral shedding was measured in nasal wash samples collected daily during the
quarantine period by means of rRT-PCR. A virtual quantification tool was applied to the rRT-PCR Ct values to generate an estimate of viral copy
number [14]. The graph shows the mean copy number + SEM from subjects who became infected.











































10Nasal dischargeViral shedding Symptoms
Figure 3 Kinetics of clinical illness and virus infectivity. A. The clinical symptom score, nasal discharge weight (g) and virus shedding by
TCID50 are presented across the quarantine period for subjects in cohort 3 only (N = 12). Data is shown as mean ± SEM.
Watson et al. Virology Journal  (2015) 12:13 Page 6 of 9inhibitors thereby offering a rescue therapy for future
clinical use, if required. We clinically tested the infectivity
of the virus in a dose-escalation study in sero-negative
healthy adult volunteers. Results from the optimal cohort
showed laboratory-confirmed infection in 75% of subjects
defined by at least one mild or worse symptom/sign and
lab-confirmed infection.
The virus induced a mild-moderate disease without
such severity to be of clinical concern. At the highest
dose, physician-reported signs of infection were classi-
fied as mild (100%), moderate (58%) and severe (16%). It
is important to note that classifications used for mild,
moderate or severe relate to influenza infection in the
context of the challenge model and do not necessarily
reflect medial definitions of clinical severity. It was consid-
ered that this mixed profile disease severity was suitable
for use in intervention studies as this provides a window
for reduction without causing overt safety concerns. Influ-
enza challenge studies can be criticised for not mimicking
the symptoms of naturally acquired influenza infection.
However, whilst challenge studies are restricted to deliver
an acceptable safety profile, many individuals with natur-
ally acquired influenza infection will have a wide range of
symptoms, most of which are not severe.
As of 2008, 532 of approximately 1,300 volunteers
who have participated in human influenza challenge
studies were administered A/H1N1 viruses [7]. Almost all
of these studies enrolled healthy adult volunteers <50 years
of age with low (≤1:16) pre-existing HI antibody against
the challenge strain. In this study, we only observed ser-
conversion from 48% of subjects after virus challenge.
Additional testing of serum using more sensitive tech-
niques, such as the virus microneutralisation assay, may
increase the proportion of subjects with virus-specific
antibody responses. However, preliminary testing using
samples from cohort 3 did not show an increase inseroconversion using the microneautralisation assay
(data not shown). Other studies have also reported
incomplete serological responses in subjects after influ-
enza challenge using an HAI assay [8-10]. It is possible
that the kinetics of antibody production differs between
subjects possibly influenced by the extent of previous
exposure to influenza viruses.
The safety profile was such that physiological responses
to viral infection were detected (elevated C-reactive pro-
tein and elevated monocytes, pyrexia and upper respira-
tory tract symptoms), but were not of such severity to
cause irreversible damage or be of clinical concern. Most
importantly there were no significant changes in the re-
spiratory function of subjects and no subjects experienced
any adverse cardiovascular effects. Most treatment emer-
gent adverse events recorded (37 in total over the whole
study) were predominantly considered to be related to the
virus. There were no clinically-relevant changes in clinical
chemistry or haematology parameters but, interestingly,
there was a significant inverse correlation between
lymphocyte to monocyte ratio (L:M) and clinical symp-
toms or scores 5 days after inoculation. These findings
were aligned with a recent report suggesting that a L:M
ratio of <2 correctly identified subjects infected with influ-
enza at the time of maximal symptoms [11]. Pyrexia
(>37.7°C) was measured in 7 subjects, with no association
to virus dose, but was concomitant with increased C-
reactive protein in 6 out of the 7 subjects.
We used two independent assessments of illness,
subject-reported symptoms and physician reported signs.
Physician-reported signs were considered to be a more
objective assessment of illness and while the subject
reported symptoms were more extensive, and typically
reported for this type of clinical model, they are neverthe-
less subjective. There was a significant correlation between
the two assessments in the highest dose cohort and
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of virus, both symptoms and signs provide useful informa-
tion to define infectivity. Total nasal discharge weights
closely correlated with subject symptoms and the kinetics
of both measurements were well aligned. Whilst this asso-
ciation may not be surprising as symptoms scores include
assessment of nasal discharge, the recording of nasal
discharge weights provided a useful additional objective
measure of clinical outcome. One limitation of this study
is the lack of a control/placebo group which would allow
some understanding of non-virus related symptoms or
signs.
Kinetic analysis of mean symptoms in the optimal dose
group showed maximal illness occurred 4 days after viral
challenge, which was accompanied by peak viral shed-
ding. This is a moderately delayed onset compared to
other influenza challenge studies where peak symptom
scores occur 3 days post infection and peak viral titres
2 days after infection [7] (review), [12,13]. Surprisingly,
there was evidence of viral shedding on the day of dis-
charge from the quarantine unit (7 days post challenge).
For this study, these results were not available on dis-
charge but all subjects had a negative rapid influenza
test, highlighting the differences in sensitivity of the as-
says, and subjects were judged to be asymptomatic by
the study investigator. For future studies using this
challenge virus it would be prudent to include a longer
quarantine period and/or include the use of antiviral
agents towards the end of quarantine. Alternatively, sub-
jects should remain in the quarantine facility until a nega-
tive PCR result is obtained.
In conclusion, the human influenza challenge model
offers potential as a more controlled, rapid, and cost
efficient way in which to clinically test influenza vaccines
as compared to community-based studies or field trials.
We have manufactured an influenza A/H1N1 virus under
GMP conditions and have clinically characterised the in-
fectivity profile of the virus as a suitable agent to use in a
human influenza challenge model.
Materials and methods
Characterisation of A/H1N1 challenge strain
The virus was isolated from a combined nasal/throat
swab collected from an otherwise healthy 3 year-old boy
exhibiting typical influenza-like illness in June 2009. The
boy was a prospectively enrolled participant in an Inves-
tigational Review Board-approved influenza pathogen-
esis study (DMID 07-0090) conducted by University of
Rochester Medical Centre as part of the New York
Influenza Centre of Excellence. Informed written parental
consent was obtained for the use of the isolated virus.
Influenza A/California/2009 (H1N1) infection was con-
firmed by polymerase chain reaction (PCR). Exclusion of
concomitant infection with other viruses was evaluated byPCR and serology. Medical and family histories were
negative at the time of the initial encounter and the boy
was confirmed to have remained healthy when the family
was re-contacted in 2012. An aliquot of this clinical sam-
ple was inoculated into the allantoic fluid of SPF embryo-
nated hen eggs and expanded to GMP standards by
Meridian Bioscience Inc. (OH, USA). Allantoic fluid from
the 3rd passage was pooled and diluted 1:5 in 37.5% su-
crose phosphate glutamate as a preservative. The solution
was sterile filtered and was distributed into over 2000
cryovials at 0.7 mL/vial and stored at ≤ -65°C. The virus
stock had a titre of 7 × 107 TCID50/mL. Genetic sequen-
cing showed the virus to have >99.4% sequence identity to
A/California/04/2009 HA and NA proteins (for sequence
data refer to online additional material). This identity was
confirmed serologically using reference sera in an HAI
assay (1:1600). Extensive adventitious agents testing con-
firmed the absence of concomitant infectious agents.
Using an in vitro NA inhibition assay, the A/H1N1 chal-
lenge strain was shown to be susceptible to oseltamivir
and zanamivir with IC50 values of 0.14 and 0.24 nM
respectively.
Volunteers
The subjects were healthy adults aged 18 to 45 and sero-
logically negative to the challenge virus (serum HAI
titres ≤1:10) (Table 1). Detailed inclusion/exclusion cri-
teria are described in clinicaltrials.gov under identifier
NCT02014870 and in the online additional material. All
subjects gave written informed consent to participate in
the trial. The protocol and informed consent were ap-
proved by an independent ethics committee, Institutional
Review Board, ZNA/OCMW, Antwerp, Belgium. The study
was conducted in accordance with EU Directive 2001/20/
EC and ICH GCP. The study was initiated in June 2013
and completed in October 2013.
Clinical trial
The study was an open label, dose-ascending, non-
controlled, first-time-in-human study to assess safety,
tolerability and illness/infectivity profile of the influenza
challenge strain. The study was conducted in purpose-
built isolation unit at SGS, Antwerp, Belgium. Three co-
horts were employed: the first cohort were inoculated
with a 1:1000 dilution of neat virus (estimated TCID50 of
3.5 × 104) and was increased by 10-fold for two subse-
quent cohorts (1:100 and 1:10 dilution of neat virus). Sub-
jects entered the quarantine unit 24 hrs prior to virus
challenge and remained for an additional 7 days.
Immediately before challenge, frozen virus was thawed
rapidly in a 37°C water bath before dilution in pre-warmed
(37°C) phosphate-buffered saline (PBS, Mediatech) to ap-
propriate challenge dose. Subjects were placed in a semi-
recumbent position, with the head tipped slightly back and
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diluted virus stock was administered intranasally to each
subject (0.25 mL per nostril) using a pipette.
Symptoms were captured twice daily by self-reporting
on 16 events associated with influenza illness (headache,
nasal stuffiness, runny nose, sore throat, sneezing, hoarse-
ness, earache, facial or eye pain, cough, wheezy chest,
breathing difficulty, musculoskeletal ache, nausea/vomit-
ing, feeling/hot/feverish/chills/rigor, fatigue and diarrhoea)
and classified as absent, mild, moderate or severe. Classifi-
cations were defined as follows: mild: the event causes a
minor discomfort, does not interfere with daily activity of
the subject or does not lead to establishment of a correct-
ing treatment; moderate: the event perturbs the usual
activity of the subject and is of a sufficient severity to
make the subject uncomfortable; severe: the event pre-
vents any usual routine activity of the patient and causes
severe discomfort. In addition, a more objective targeted
physical exam was performed twice daily by the study
physician which assessed 6 clinical parameters (nasal dis-
charge, otitis, pharyngitis, sinus tenderness, new wheezes,
crackles or rhonchi on lung auscultation and percussion)
using the same classification system. Vital signs and safety
laboratory tests were performed daily. Temperature was
measured twice daily (oral for cohort 1 and tympanic for
cohorts 2 and 3). Nasal washes were performed daily by
instilling 5 mL of pre-warmed (37°C) sterile phosphate-
buffered saline into each nostril and the effluent was
collected, diluted 1:1 in virus transport medium (refer to
WHO publication detailed below) and stored at ≤ -65°C.
Daily nasal-discharge weights were determined by the col-
lection of pre-weighed tissues in pre-weighed plastic bags
assigned to each subject during each 24-hour period. On
the day of discharge from the quarantine unit subjects
were required to have negative result from a negative
rapid influenza test (Directigen™ EZ Flu A + B, BD). Follo-
wing completion of each cohort, a safety review commit-
tee reviewed symptom and viral shedding data (rRT-PCR)
before recommending to proceed to the next cohort.
Laboratory analysis
Influenza serology was performed using a hemagglu-
tination-inhibition (HI) assay at screening (SGS Life
Sciences) and at Day -1 and 29 (VisMederi srl, Siena,
Italy) for all cohorts. Serum was pre-treated with
receptor-destroying enzyme (RDE) II (Denka Seiken,
Japan) and 2-fold serially diluted starting from a dilu-
tion of 1:10 to 1:2560 in physiological saline. Virus
(A/H1N1/California/04/2009, NIBSC) was added to
each well at 4 hemagglutination units (HAU)/50 μL
for 1 h at room temperature, followed by 0.35% turkey
red blood cells for 1 h at room temperature. Refer-
ence sheep hyperimmune antisera were provided by
NIBSC.For real-time RT-PCR (rRT-PCR), the WHO protocol
“CDC protocol of real-time RT-PCR for swine influenza
A(H1N1)” was followed by VisMederi srl using but only
the InfA primer designed for the universal detection in-
fluenza A viruses. A specimen was considered positive
for influenza A if cycle threshold (Ct) values were within
Ct values of 40. A virtual quantification tool was applied
to the Ct values to allow the conversion of CDC
rRT-PCR Ct values to virus RNA copy number, in the
absence of a standard curve run in parallel to the
samples [14].
Additional analysis of nasal wash samples from cohort
3 (but not cohorts 1 or 2) was conducted using a TCID50
(Tissue Culture Infectious Dose 50%) assay by Virocli-
nics Biosciences, The Netherlands. For the TCID50 assay,
serial ten-fold dilutions of the nasal wash samples were
inoculated onto a monolayer of MDCK cells and in-
cubated for 6 days at 37°C. The presence of virus was
detected using a HI assay and the infectious virus ti-
tres are calculated using the Spearman and Kaerber
method [15,16].
Statistics and definitions
Comparisons of clinical scores with other parameters were
performed by Pearson correlation. No formal sample size
calculations were performed. The pre-defined definitions
of attack rate were 1. Incidence of subjects experiencing at
least one day with one mild subject-reported symptom or
physician-reported sign and laboratory-confirmed infec-
tion or 2. Incidence of subjects experiencing at least one
day with one moderate or higher subject-reported symp-
tom or physician-reported sign and laboratory-confirmed
infection. Clinical illness is defined as one mild or
moderate (as appropriate) subject-reported symptom
or physician-reported sign recorded from 1 to 7 days
after inoculation. Daily total symptom or sign scores
were calculated using the worst grade recorded on
each day, for each symptom summed, using a scoring
system of 0-3 relating to absent, mild, moderate and
severe symptoms respectively. Total symptom or sign
scores were calculated as the sum of the daily scores
from post-infection to discharge.
Additional file
Additional file 1: Adverse events; clinical study inclusion and
exclusion criteria; sequencing data from virus HA and NA proteins.
Detailed description and table of adverse events during the quarantine
period; full listing of clinical study inclusion and exclusion criteria;
sequence data of challenge virus HA and NA proteins compared to
A/California/4/2009 and A/California/7/2009.
Abbreviations
TCID50: Tissue Culture Infectious Dose 50%; WHO: World Health Organisation;
rRT-PCR: Real-time reverse transcription Polymerase Chain Reaction;
L:M: Lymphocyte:Monocyte; GMP: Good Manufacturing Practice;
Watson et al. Virology Journal  (2015) 12:13 Page 9 of 9HI: Heamagglunination inhibition; CRP: C-reactive protein; TEAE: Treatment
emergent adverse event; AE: Adverse event; MDCK: Madin-Darby canine
kidney; CDC: Centers for Disease and Control and Prevention; NIBSC: National
Institute for Biological Standards and Control.
Competing interests
JW, JF, GF, BG and CB are employees of Immune Targeting Systems and
hold share options in the company. JM and PP are paid consultants for
Immune Targeting Systems and JM holds share options in the company.
The authors declare they have no other competing interests.
Authors’ contributions
JT provided the clinical viral sample and initial characterisation. JW, BG, GF,
CB and JM co-ordinated the manufacture and full characterisation of the
virus. CB, SM, JF and JW significantly contributed to the design, conduct and
analysis of the clinical trial; JF analysed the clinical trial data, performed the
statistical analysis and wrote the first draft of the manuscript. All authors
provided important intellectual content and review of the manuscript.
All authors read and approved the final manuscript for publication.
Acknowledgements
The authors would like to acknowledge the following organisations for the
manufacture and characterisation of the virus: Meridian Life Science Inc., USA
(GMP manufacture and release testing); Southern Research Institute, USA
(in vitro testing); Bioqual Inc., USA (in vitro/in vivo testing); SGS Life Science
Services, Belgium (clinical testing); Vismederi, Italy (virology); Viroclinics,
Netherlands (virology). Influenza antigens and control sera were obtained
through the Influenza Reagent Resource, Influenza Division, WHO
Collaborating Center for Surveillance, Epidemiology and Control of Influenza,
Centers for Disease Control and Prevention, Atlanta, GA, USA. The authors
would also like to acknowledge Dr Peter Treasure and Dr Geoff Kitson for
their valuable input into the clinical study.
Author details
1Immune Targeting Systems Ltd, London BioScience Innovation Centre, 2
Royal College Street, London NW1 0NH, UK. 2SGS LSS, Clinical Research Unit,
Antwerpen, Belgium. 3Jill Makin Consulting Ltd, 7 Cholmondeley Road, West
Kirby, Wirral CH48 7HB, UK. 4Biologics Consulting Group, INC, 1317 King
Street, Alexandria, VA 22314, USA. 5University of Rochester Medical Center,
601 Elmwood Avenue, Box 689, Rochester, NY 14642, USA.
Received: 3 July 2014 Accepted: 13 January 2015
References
1. Gasparini R, Amicizia D, Lai PL, Panatto D. Clinical and socioeconomic
impact of seasonal and pandemic influenza in adults and the elderly. Hum
Vaccin Immunother. 2012;8:21–8.
2. Simonsen L, Clarke MJ, Schonberger LB, Arden NH, Cox NJ, Fukuda K.
Pandemic versus epidemic influenza mortality: a pattern of changing age
distribution. J Infect Dis. 1998;178:53–60.
3. Kang SM, Song JM, Compans RW. Novel vaccines against influenza viruses.
Virus Res. 2011;162:31–8.
4. Osterhaus A, Fouchier R, Rimmelzwaan G. Towards universal influenza
vaccines? Philos Trans R Soc Lond B Biol Sci. 2011;366:2766–73.
5. Gilbert SC. Advances in the development of universal influenza vaccines.
Influenza Other Respir Viruses. 2013;7:750–8.
6. Hurt AC. The epidemiology and spread of drug resistant human influenza
viruses. Curr Opin Virol. 2014;8C:22–9.
7. Carrat F, Vergu E, Ferguson NM, Lemaitre M, Cauchemez S, Leach S, et al.
Time lines of infection and disease in human influenza: a review of
volunteer challenge studies. Am J Epidemiol. 2008;167:775–85.
8. Killingley B, Enstone J, Booy R, Hayward A, Oxford J, Ferguson N, et al.
Potential role of human challenge studies for investigation of influenza
transmission. Lancet Infect Dis. 2011;11:879–86.
9. Lillie PJ, Berthoud TK, Powell TJ, Lambe T, Mullarkey C, Spencer AJ, et al.
Preliminary assessment of the efficacy of a T-cell-based influenza vaccine,
MVA-NP +M1, in humans. Clin Infect Dis. 2012;55:19–25.
10. Huang KY, Li CK, Clutterbuck E, Chui C, Wilkinson T, Gilbert A, et al.
Virus-specific antibody secreting cell, memory B-cell, and sero-antibodyresponses in the human influenza challenge model. J Infect Dis.
2014;209:1354–61.
11. McClain MT, Park LP, Nicholson B, Veldman T, Zaas AK, Turner R, et al.
Longitudinal analysis of leukocyte differentials in peripheral blood of
patients with acute respiratory viral infections. J Clin Virol. 2013;58:689–95.
12. Wilkinson TM, Li CK, Chui CS, Huang AK, Perkins M, Liebner JC, et al.
Preexisting influenza-specific CD4+ T cells correlate with disease protection
against influenza challenge in humans. Nat Med. 2012;18:274–80.
13. Bagga B, Woods CW, Veldman TH, Gilbert A, Mann A, Balaratnam G, et al.
Comparing influenza and RSV viral and disease dynamics in experimentally
infected adults predicts clinical effectiveness of RSV antivirals. Antivir Ther.
2013;18:785–91.
14. Piralla A, Daleno C, Pariani E, Conaldi P, Esposito S, Zanetti A, et al. Virtual
quantification of influenza A virus load by real-time RT-PCR. J Clin Virol.
2013;56:65–8.
15. Spearman C. The method of 'right and wrong cases' ('constant stimuli')
without Gauss's formulae. Br J Psychol. 1908;2:227–42.
16. Kaerber G. Beitrag zur Kollektiven Behandlung Pharmakologischer
Reihenversuche. Arch Exp Path Pharma. 1931;162:480–7.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
